

Resource Summary Report

Generated by [dkNET](#) on Aug 11, 2026

HA-HIF2alpha-pcDNA3

RRID:Addgene_18950

Type: Plasmid

Proper Citation

RRID:Addgene_18950

Plasmid Information

URL: <http://www.addgene.org/18950>

Proper Citation: RRID:Addgene_18950

Insert Name: Hypoxia inducible factor 2 alpha

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:12086860](#)

Vector Backbone Description: Backbone Marker:Invitrogen; Backbone Size:5433; Vector Backbone:pcDNA3; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Plasmid Name: HA-HIF2alpha-pcDNA3

Relevant Mutation: wt cDNA

Record Creation Time: 20220422T222043+0000

Record Last Update: 20260808T081347+0000

Ratings and Alerts

No rating or validation information has been found for HA-HIF2alpha-pcDNA3.

No alerts have been found for HA-HIF2alpha-pcDNA3.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Heritz JA, et al. (2026) Targeting and dissociating HIF2 α from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer. *Communications medicine*, 6(1), 91.

Harada A, et al. (2025) Hypoxia-induced Wnt5a-secreting fibroblasts promote colon cancer progression. *Nature communications*, 16(1), 3653.

Purandare N, et al. (2025) Pseudohypoxia-Stabilized HIF2 α Transcriptionally Inhibits MNRR1, a Druggable Target in MELAS. *Cells*, 14(14).

Suh J, et al. (2024) Decoupling NAD⁺ metabolic dependency in chondrosarcoma by targeting the SIRT1-HIF-2 α axis. *Cell reports. Medicine*, 5(1), 101342.

Ruan W, et al. (2024) The BMAL1/HIF2A heterodimer modulates circadian variations of myocardial injury. *Research square*.

Wang S, et al. (2023) CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion. *The Journal of clinical investigation*, 133(23).

Kumar N, et al. (2023) Histone acetyltransferase 1 (HAT1) acetylates hypoxia-inducible factor 2 alpha (HIF2A) to execute hypoxia response. *Biochimica et biophysica acta. Gene regulatory mechanisms*, 1866(1), 194900.

Jacquier V, et al. (2022) RIP140 inhibits glycolysis-dependent proliferation of breast cancer cells by regulating GLUT3 expression through transcriptional crosstalk between hypoxia induced factor and p53. *Cellular and molecular life sciences : CMLS*, 79(5), 270.

Riedl T, et al. (2021) Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence. *Hepatology (Baltimore, Md.)*, 74(4), 1766.

Ivanova E, et al. (2021) DYRK3 contributes to differentiation and hypoxic control in neuroblastoma. *Biochemical and biophysical research communications*, 567, 215.

Lu H, et al. (2021) HIF-1 recruits NANOG as a coactivator for TERT gene transcription in hypoxic breast cancer stem cells. *Cell reports*, 36(13), 109757.

Méndez-Solís O, et al. (2021) Kaposi's sarcoma herpesvirus activates the hypoxia response to usurp HIF2 α -dependent translation initiation for replication and oncogenesis. *Cell reports*, 37(13), 110144.

Soyal SM, et al. (2020) The Expression of CNS-Specific PPARGC1A Transcripts Is Regulated by Hypoxia and a Variable GT Repeat Polymorphism. *Molecular neurobiology*, 57(2), 752.

Yoo HC, et al. (2020) A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells. *Cell metabolism*, 31(2), 267.

Yu J, et al. (2020) A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia. *Aging*, 12(7), 5781.

Kim H, et al. (2020) A system-level approach identifies HIF-2 α as a critical regulator of chondrosarcoma progression. *Nature communications*, 11(1), 5023.

Senavirathna LK, et al. (2018) Hypoxia induces pulmonary fibroblast proliferation through NFAT signaling. *Scientific reports*, 8(1), 2709.

Faria M, et al. (2018) The estrogen receptor variants α 2 and α 5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling. *Oncotarget*, 9(91), 36273.

Zhuang Z, et al. (2016) HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma. *Endocrine-related cancer*, 23(5), L13.

Taïeb D, et al. (2016) Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. *Journal of neuro-oncology*, 126(3), 473.